USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

Main Article Content

Paola Mancino
Katia Falasca
Claudio Ucciferri
Eligio Pizzigallo
Jacopo Vecchiet *
(*) Corresponding Author:
Jacopo Vecchiet | jvecchiet@unich.it

Abstract

Haematological abnormalities are common during combination antiviral therapy for chronic hepatitis C. Although dose reduction or discontinuation can easily treat these side effects, they can adversely affect the efficacy of combination antiviral therapy reducing the likelihood of a sustained viral response (SVR). To avoid potentially diminishing a patient’s chance of response, many physicians have begun using growth factors off-label to manage anaemia and neutropenia in hepatitis C. Haematopoietic growth factors are generally well tolerated and they may be useful for managing haematological side effects of anti-HCV therapy improving patients’ quality of life. To date, the role and benefit of these agents during anti-HCV therapy and their positive impact on SVR have not conclusively determined in the published studies. However, the possibility of a benefit to individual outpatients remains, and an individualized approach is recommended. This review explores the incidence, clinical significance, and management of anaemia, neutropenia and thrombocytopenia associated with combination therapy for HCV infection.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

Paola Mancino, Università di Chieti

Clinic of Infectious Diseases,Dept. of Medicine and Science of Aging. University "G. d'Annunzio" – School of Medicine, Via dei Vestini, 66013 Chieti - Italy

Jacopo Vecchiet

Clinic of Infectious Diseases,Dept. of Medicine and Science of Aging. University "G. d'Annunzio" – School of Medicine, Via dei Vestini, 66013 Chieti - Italy